Disrupting the vicious cycles of chronic inflammation

AQILION

Our passion and focus



Image courtesy of NIEHS

IN BRIEF

ABOUT AQILION

- Biotech company developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions
- Active in early phases of drug discovery, from idea to early clinical development

Aqilion's team combines big pharma experience with an entrepreneurial mindset and drive

Projects are driven internally in close collaboration with a network of highly experienced service providers and consultants possessing specialized cutting-edge knowledge and technologies

Headquartered in Helsingborg Sweden

VALUE CREATION

AQ pipeline:

Regulus: AQ280 – a super selective JAK1 inhibitor
Phase 1 started Augyust 2022
Chronic inflammation in esophagus driven by eosinophilic infiltration as first indication.

Alnitak: Best in class TAK1 inhibitor program with promising features in several indications. Verified external interest in asset. CD selection in H2:2022

Girtab: Launched May 9, 2022

Polaris: Dx program with focus on inflammasome biology

AQ Dx – new target nominations → future programs

PIPELINE

Program	Target	Drug Candidate	Target Discovery	Development of candidate drug	IND enabling preclinical development	Phase 1	Phase 2
Regulus	JAK1	AQ280					
Girtab	Ahr	AQ312					
Alnitak	TAK1	Not disclosed					
Alnitak	TAK1 CNS penetrant	Not disclosed					
Polaris	Not disclosed	Not disclosed					

CLEAR FOCUS



HISTORY & LEGACY

2018-2019: New CEO , team, BoDs and strategy. MSEK 200 to finance the new direction

2019: New name - AQILION

2022: Biotech with internal pipeline of 3 programs

AQILION

Aqilion’s experienced team and BoDs

have successfully shepherded drugs all the way from discovery to market

A genuine track record from medical science and drug development combined with entrepreneurial drive is the core of the Aqilion team

Sarah Fredriksson
Chief executive officer

Johan Lund
Chief Scientific Officer

Jan Törnell
Chief Medical Scientist

Fredrik Lindgren
Chief Business Officer

Martin Johansson
Senior Director Medicinal Chemistry

Anneli Tinnerholm
Senior Director Clinical Operations

Torgeir Vaage
Chief Financial Officer

Anneli Hällgren
Senior Director Preclinical Development

Carina Eldh
Chief Controlling Officer

Key objective is to block the messengers and pro-inflammatory mediators

- An inflammatory cytokine is a signalling molecule that is secreted from immune cells and certain other cell types that promotes inflammation
- If the cytokines are hindered the message of inflammation boost is lost
- Diseases can be grouped according to cytokine profiles



Biologics have validated cytokines as clinically relevant mediators and shown **limitations with mono-target** therapeutics

- Biologics have been very successful (commercially and clinically)

- Biologics (e.g. antibodies) target single inflammatory signaling molecules (cytokines) thus validating the clinical relevance of different cytokines

- Disadvantages using biologics
  - many non-responders
  - resistance can develop over time
  - the relative importance of different cytokines in different inflammatory disorders vary

Drug	2020 sales (bUSD)
Humira (a-TNF)	20
Dupixent (a-IL4/13)	8
Stelara (a-IL12/23)	8
Enbrel (a-TNF)	5
Cosentyx (a-IL17)	4
Remicade (a-TNF)	4
Actemra (a-IL6)	3
Ilaris (a-IL1b)	1

Kinases are our prioritized drug targets

- Highly succesful drug target class
- Inhibitors approved in many indications including oncology and inflammatory diseases
- Regulate multiple cytokines – act as inflammatory nodes and regulators
- Amendable to structure-based drug design (SBDD)



AQILION

Aqilion's approach: affect multiple mechanisms using small molecules

When several pro-inflammatory mechanisms are affected, a lower dose can still promote efficacy without increasing the risk of side effects

If several pro-inflammatory mechanisms are affected, the risk of therapy resistance may be reduced

Provide greater efficacy - *Breaking the ceiling of therapeutic response in auto-immune and inflammatory diseases*

Aqilion envisions a treatment strategy based on cytokine network profiles and their regulation in diseases

Modulate signalling of multiple cytokines
(cytokine networks)

+

Match cytokine inhibition profile to cytokine dysregulation profiles in disease
(precision medicine)

↓

Increased response and efficacy – better patient outcomes



Image from NEJM



AQILION

TAK1 (Transforming growth factor-β-activated kinase 1)

TAK1 is a ”master regulator” of both NF-κB and JNK signaling

- **Un-drugged node**
  Key node in signalling pathways that integrates innate immune signalling and inflammasome activation

- **Validated Biology**
  TNFα, IL-1β, LPS/TLR are clinically validated pathways/mediators in several disease areas



AQILION

TAK1 inhibitors

Background

Several TAK1 inhibitor programs have existed with different approaches

Limitations of all known series have included; poor kinase selectivity, poor PK or limited cellular efficacy

No TAK1 inhibtor program has entered clinical trials



Pfizer



OSI



AstraZeneca



Chugai



Confluence



Myrexis



Hanmi



ZoBio BV

AQILION

TAK1

Aqilion's reason to believe

Aqilion believes that TAK1 is a druggable target that will **provide differentiated clinical efficacy** for the treatment of autoimmune and inflammatory diseases

Based on a strong hypothesis regarding the design of druglike and selective kinase inhibitors, Aqilion initiated a TAK1 inhibitor program (Alnitak) in 2019

In less than 3 years Aqilion has discovered high quality proprietary TAK1 inhibitors that display excellent druglike properties and kinase selectivity

Aqilion believes that these "best-in-class" inhibitors are highly suitable for clinical development as a novel treatment for inflammatory and autoimmune diseases

TAK1 inhibitor: ∑ oral anti-TNFa, anti-IL-1, anti-IL-6 treatment

AQILION

Highly efficacious *in vivo* in autoimmune disease model

- Collagen induced arthritis (CIA) in rats
- AQT00128 is efficacious at all tested doses following daily oral dosing in a therapeutic setting



Inhibition of TAK1 has the potential to affect a range of inflammatory and autoimmune diseases

Systemic
- Rheumatoid arthritis
- Osteoarthritis
- Fibrosis
- SLE
- Sjögren's syndrome

Skin
- Hidradenitis Suppurativa



CNS
- Multiple sclerosis
- Stroke
- Alzheimer's disease
- Parkinson's disease

Gastrointestinal
- Ulcerative colitis
- Crohn's disease

AQILION

Aqilion TAK1 inhibitor program overview

Profile	
Value proposition	• **Best-in-class TAK1 medicinal chemistry** • TAK1 is a target for the treatment of inflammatory and auto-immune diseases • Aqilion has discovered highly selective and potent TAK1 inhibitors with excellent drug-like properties within a unique chemical space • Orally bioavailable • Demonstrated *in vivo* efficacy • Inflammasome related target - TAK1 inhibition blocks NLRP3 signaling • Lead optimization ongoing • BD activities: Extended data package available under CDA • Clinical candidate to be selected Q4 2022

Lead cmpd properties	AQT00128
Biochemical TAK1 assay IC50	3 nM
logD	2.20
Molecular weight	< 450
Solubility	>95 µM
In vitro Hep clearance (h/r)	Low/Low
%F	>60%
Kinase selectivity score	0.024

AQILION

Milestones – looking forward


THANK YOU!
www.aqillion.com